Last updated: February 20, 2026
What is NDC 24208-0814?
NDC 24208-0814 is a biologic product, a monoclonal antibody used in the treatment of autoimmune conditions, primarily rheumatoid arthritis. The drug is marketed under the brand name Rinvoq (upadacitinib), developed by AbbVie.
Market Landscape
Size and Growth
- Global rheumatoid arthritis treatment market estimated at USD 21 billion in 2022.
- Projected compound annual growth rate (CAGR) of approximately 5.8% through 2030 [1].
- Biologic therapies account for about 60% of this market, with monoclonal antibodies dominating.
Key Competitors
- AbbVie Rinvoq (upadacitinib)
- Pfizer Xeljanz (tofacitinib)
- Eli Lilly Olumiant (baricitinib)
- Johnson & Johnson Stelara (ustekinumab)
Market Share
| Product |
Estimated Market Share (2022) |
Key Differentiators |
| Rinvoq |
15-20% |
High specificity, oral administration |
| Xeljanz |
20-25% |
First oral JAK inhibitor, established brand |
| Olumiant |
5-10% |
Competitive pricing, existing approval in EU |
Regulatory and Approval Status
- Approved in over 60 countries.
- FDA approval granted in August 2019.
- CE mark obtained in 2020 for EU markets.
Price Analysis
Current Pricing (U.S. Market)
- Average wholesale price (AWP): approximately USD 65,000 per year per patient.
- Negotiated prices with payers for managed care range from USD 50,000 to USD 60,000.
Price Comparison with Competitors
| Drug |
Annual Cost (USD) |
Administration |
Indications |
| Rinvoq |
55,000-60,000 |
Oral |
Rheumatoid arthritis |
| Xeljanz |
50,000-55,000 |
Oral |
Rheumatoid arthritis, UC |
| Olumiant |
40,000-50,000 |
Oral |
Rheumatoid arthritis |
Pricing Trends
- Price reductions of 5-10% anticipated in 2024 due to payer negotiations.
- Bundled rebate programs are increasingly common in managed care.
Market Drivers and Barriers
Drivers
- Rising prevalence of rheumatoid arthritis and other autoimmune diseases.
- Preference for oral treatments over injectable biologics.
- Enhanced efficacy and safety profile of Rinvoq over older agents.
Barriers
- Competition from other JAK inhibitors and biologics.
- Payer reimbursement restrictions.
- Patent expirations for biologics could lead to biosimilar entry and price erosion.
Future Price Projections (Next 5 Years)
| Year |
Estimated Price Range (USD) |
Rationale |
| 2023 |
52,000 - 60,000 |
Stable; negotiation trends |
| 2024 |
50,000 - 58,000 |
Anticipated payer pressure |
| 2025 |
48,000 - 55,000 |
Increased biosimilar competition |
| 2026 |
45,000 - 52,000 |
Biosimilars and discounting |
| 2027 |
43,000 - 50,000 |
Market saturation, price war |
Key Factors Impacting Future Pricing
- Regulatory decisions enabling biosimilar approvals.
- Expansion into additional indications increases volume.
- Strategic alliances with payers influence reimbursement.
- Long-term safety data usage can impact prescribing habits.
Key Takeaways
- NDC 24208-0814 (Rinvoq) holds a significant market position among oral JAK inhibitors.
- Price points are driven by efficacy, safety, and competition, with current USD 55,000-60,000 per year.
- Market growth forecasts remain positive, but price erosion due to biosimilar entry and payer negotiation trends is likely.
- Strategic pricing, reimbursement negotiations, and indication expansion will shape product valuation over the next five years.
FAQs
1. How does Rinvoq compare to other JAK inhibitors in terms of pricing?
Rinvoq’s annual cost is similar to Xeljanz, with a slight edge in pricing negotiating margins. Olumiant is priced lower but has a different efficacy profile.
2. Will biosimilars affect Rinvoq’s market share?
Rinvoq is a small molecule, not a biosimilar, but biosimilar biologics might indirectly impact by offering alternative treatment options at reduced prices.
3. Are there upcoming patent expirations for Rinvoq?
Rinvoq’s initial patent expires around 2030, but patent litigations or extensions could influence timing.
4. How do payer policies influence Rx pricing?
Payers restrict access based on formulary criteria, often demanding discounts or rebates, which affect the net price.
5. What future indications could expand product revenue?
Potential approvals for psoriatic arthritis, atopic dermatitis, and ulcerative colitis could increase the patient population, supporting price stability or growth.
References
[1] MarketResearch.com. (2022). Global Rheumatoid Arthritis Market Forecast. Retrieved from https://www.marketresearch.com
